Cost-effectiveness of 3-Hydroxy-3-Methylglutaryl–Coenzyme A Reductase Inhibitors in the Secondary Prevention of Cardiovascular Disease

Abstract
CARDIOVASCULAR disease (CVD), including coronary heart disease (CHD) and stroke, is the leading cause of death in most industrialized countries.1 Accordingly, much attention has been focused on recent clinical trials demonstrating that lipid modification with 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors (statins) can reduce the morbidity and mortality of secondary events among adults diagnosed as having CHD.2-4

This publication has 15 references indexed in Scilit: